Diabetic macular edema: Evidence-based management

Area of Science:

• Ophthalmology
• Endocrinology
• Vascular Biology

Background:

• Diabetic macular edema (DME) is a leading cause of vision loss in diabetic retinopathy patients.
• Its prevalence is increasing with the global rise in type 2 diabetes.
• Pathophysiology involves retinal hypoxia, VEGF upregulation, and altered vascular autoregulation.

Purpose of the Study:

• To review the current understanding of DME pathophysiology and treatment.
• To highlight the limitations of existing therapies and the need for new interventions.
• To discuss ongoing research into novel pharmacological targets for DME.

Main Methods:

• Review of existing literature on diabetic macular edema.
• Analysis of current diagnostic tools like spectral domain optical coherence tomography (SD-OCT).
• Evaluation of established and emerging treatment modalities for DME.

Main Results:

• SD-OCT is crucial for assessing DME.
• Metabolic control (hyperglycemia, blood pressure) is foundational.
• Current treatments (anti-VEGF, corticosteroids, laser, vitrectomy) have incomplete response rates.
• Significant visual loss and structural damage persist in a subset of patients.

Conclusions:

• Despite current treatments, a substantial portion of DME patients experience incomplete recovery.
• Innovation in ophthalmic care delivery and cost reduction are key areas of focus.
• Research into alternative biochemical pathways offers promise for treating refractory DME cases.